LQDA NASDAQ
Liquidia Corporation
1W: -58.1%
1M: -58.9%
3M: -63.8%
YTD: -8.8%
1Y: +29.9%
3Y: +348.2%
5Y: +897.9%
$28.64
+0.65 (+2.32%)
Weekly Expected Move ±29.6%
$12
$20
$29
$37
$46
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
23 relationships23
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-04-13
Earliest Filing
2025-10-30
Latest Filing
partner: 16
investor: 3
acquirer: 2
supplier: 2
Counterparties (Filed by LQDA)
23 relationshipsCompanies named in LQDA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Liquidia Technologies, Inc. | LQDA | partner | Entered into an exclusive licensing agreement with Vectura for treprostinil products | 2025-10-30 | View |
| Liquidia Corporation | LQDA | partner | Parent company of Liquidia Technologies, Inc. | 2025-10-30 | View |
| Vectura Limited | — | partner | Partnered with Liquidia Technologies for exclusive rights to develop and commercialize treprostinil products in the US | 2025-10-30 | View |
| Liquidia Corporation | LQDA | acquirer | Parent company of the Tenant entering into a lease agreement. | 2025-06-18 | View |
| Liquidia Technologies, Inc. | LQDA | acquirer | Wholly owned subsidiary of Liquidia Corporation entering into a lease agreement. | 2025-06-18 | View |
| King Combs LLC | — | partner | Landlord providing the manufacturing facility premises under a lease agreement. | 2025-06-18 | View |
| Liquidia Technologies, Inc. | LQDA | partner | Tenant entering lease amendment with Landlord | 2024-11-26 | View |
| Liquidia Corporation | LQDA | partner | Parent company of the Tenant | 2024-11-26 | View |
| Durham Keystone Tech 4, LLC | — | partner | Landlord entering lease amendment with Tenant | 2024-11-26 | View |
| Pharmosa Biopharm Inc. | — | partner | Partnered with Liquidia Technologies for exclusive licensing of L606 development in North America and smart-technology n | 2024-10-02 | View |
| Legend Aggregator, LP | — | investor | Investor purchasing common stock in a private placement | 2024-01-05 | View |
| Lonza Tampa LLC | — | supplier | Supplier of encapsulation and packaging services for YUTREPIATM inhalation powder. | 2023-07-17 | View |
| Pharmosa Biopharm Inc. | — | partner | Partnered with Liquidia for exclusive North American licensing and manufacturing of L606 | 2023-06-28 | View |
| United Therapeutics Corporation | UTHR | partner | Counterparty in ongoing patent litigation affecting financing tranches | 2023-06-28 | View |
| Plastiape SpA | — | supplier | Plastiape SpA entered into a Supply Agreement to manufacture and deliver dry powder inhalers for Liquidia Corporation's | 2023-06-08 | View |
| Glaxo Group Limited | — | partner | Entered into a Research License Agreement for pre-clinical research and development of inhaled formulations using Liquid | 2023-04-03 | View |
| Sandoz Inc. | — | partner | Partner in a Fourth Amendment to a Promotion Agreement regarding CADD-MS 3 pump repair, servicing, and profit sharing. | 2023-03-16 | View |
| HealthCare Royalty Partners IV, L.P. | — | investor | Investor in Revenue Interest Financing Agreement | 2023-01-09 | View |
| HealthCare Royalty Management, LLC | — | partner | Counterparty to Revenue Interest Financing Agreement | 2023-01-09 | View |
| United Therapeutics Corporation | UTHR | partner | Counterparty in ongoing patent litigation triggering potential funding | 2023-01-09 | View |
| Liquidia PAH, LLC | LQDA | partner | Member of Company Group under the Loan and Security Agreement | 2023-01-09 | View |
| Sandoz Inc. | — | partner | Partner in a Third Amendment to Promotion Agreement regarding a new pump development for treprostinil. | 2022-11-25 | View |
| Caligan Partners LP | — | investor | Investor in private placement of common stock and party to standstill agreement. | 2021-04-13 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-30 | Other Events; Exhibits | View | |
| 2026-09-03 | Other Events; Exhibits | View | |
| 2026-08-12 | Earnings Release; Other Events; Exhibits | View | |
| 2026-06-17 | Shareholder Vote; Exhibits | View | |
| 2026-06-08 | Other Events; Exhibits | View | |
| 2026-03-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-09 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-30 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-08-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-01 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-06-24 | Other Events; Financial Statements and Exhibits | View | |
| 2025-06-18 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-06-18 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-06-02 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-23 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-12 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-08 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-05 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR